In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA (ACIU), with a price target of $11.00. The company’s shares closed last Wednesday at $4.80, close to its 52-week low of $4.07.
According to TipRanks.com, Fein is a 3-star analyst with an average return of 1.6% and a 41.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AC Immune SA with a $14.00 average price target.
See today’s analyst top recommended stocks >>
Based on AC Immune SA’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.28 million and GAAP net loss of $15.74 million. In comparison, last year the company earned revenue of $1.51 million and had a GAAP net loss of $16.9 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
